{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.71","value":"-7.5"},{"groupId":"OG001","spread":"2.82","value":"-13.6"},{"groupId":"OG002","spread":"2.75","value":"-10.0"}]}],"title":"Change from Baseline at Week 4 [N=58; 53; 56]"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.77","value":"-11.6"},{"groupId":"OG001","spread":"2.76","value":"-21.9"},{"groupId":"OG002","spread":"2.86","value":"-19.3"}]}],"title":"Change from Baseline at Week 8 [N=57; 57; 53]"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.32","value":"-15.1"},{"groupId":"OG001","spread":"3.35","value":"-19.3"},{"groupId":"OG002","spread":"3.44","value":"-17.4"}]}],"title":"Change from Baseline at Week 12 [N=54; 53; 51]"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.15","value":"-14.0"},{"groupId":"OG001","spread":"3.21","value":"-20.1"},{"groupId":"OG002","spread":"3.20","value":"-18.6"}]}],"title":"Change from Baseline at EOT [N=60; 57; 58]"}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"58"}],"units":"Participants"}],"description":"The degree to which urinary symptoms bothered participants was assessed by the ICIQ MaleLUTS questionnaire which consists of 13 symptom bother questions each on a 0-10 scale (larger scores correspond to worse outcomes). The total bother score ranges from 0 to 130.\n\nLeast squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate.","dispersionType":"Standard Error","groups":[{"description":"Participants received matching mirabegron placebo tablets orally once daily for 12 weeks.","id":"OG000","title":"Placebo"},{"description":"Participants received 50 mg mirabegron tablets orally once daily for 12 weeks.","id":"OG001","title":"Mirabegron 50 mg"},{"description":"Participants received 100 mg mirabegron tablets orally once daily for 12 weeks.","id":"OG002","title":"Mirabegron 100 mg"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"The Full Analysis Set included all patients who received at least 1 dose of double-blind study drug \\& had both Qmax \\& PdetQmax measurements at baseline \\& 1 or both at any postbaseline on-treatment visit. End of treatment (EOT) includes the last on-treatment assessment for patients who didn't complete Week 12; N is the number of patients included.","reportingStatus":"POSTED","timeFrame":"Baseline and Weeks 4, 8 and 12","title":"Change From Baseline to Weeks 4, 8, 12 and End of Treatment in International Consultation on Incontinence Questionnaire - Male Lower Urinary Tract Symptom (ICIQ MLUTS) Total Bother Score","type":"SECONDARY","unitOfMeasure":"scores on a scale"}